Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma
Patients with Plasmacytomas

J 2022

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

ŠTORK, Martin; Sabina ŠEVČÍKOVÁ; Tomas JELINEK; Jiri MINARIK; Jakub RADOCHA et al.

Základní údaje

Originální název

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

Autoři

Vydání

Biomedicines, Basel, MDPI, 2022, 2227-9059

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.700

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00126873

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

multiple myeloma; risk factors; survival; plasmacytomas

Štítky

14110212, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 1. 2023 14:20, Mgr. Tereza Miškechová

Anotace

V originále

In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients’ data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bone-marrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0–NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and ≥3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4–28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3–67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.

Návaznosti

LX22NPO5102, projekt VaV

Název: Národní ústav pro výzkum rakoviny (Akronym: NÚVR)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní ústav pro výzkum rakoviny, 5.1 EXCELES

MUNI/A/1391/2021, interní kód MU

Název: Molekulární, buněčná, tkáňová a systémová patofyziologie vybraných komplexních nemocí (Akronym: KOMPLEX_PF)

Investor: Masarykova univerzita, Molekulární, buněčná, tkáňová a systémová patofyziologie vybraných komplexních nemocí

NU21-03-00076, projekt VaV

Název: Využití MALDI-TOF hmotnostní spektrometrie pro identifikaci molekulárních vzorců u relabovaných pacientů s mnohočetným myelomem

Investor: Ministerstvo zdravotnictví ČR, Využití MALDI-TOF hmotnostní spektrometrie pro identifikaci molekulárních vzorců u relabovaných pacientů s mnohočetným myelomem, Podprogram 1 - standardní

Přiložené soubory

Unexpected_Heterogeneity_of_Newly_Diagnosed_Multiple_Myeloma_Patients_with_Plasmacytomas.pdf

Citovat

ŠTORK, Martin; Sabina ŠEVČÍKOVÁ; Tomas JELINEK; Jiri MINARIK; Jakub RADOCHA; Tomas PIKA; Lenka POSPISILOVA; Ivan SPICKA; Jan STRAUB; Petr PAVLICEK; Alexandra JUNGOVA; Zdeňka KNECHTOVÁ; Viera SANDECKÁ; Vladimir MAISNAR; Rroman HAJEK a Luděk POUR. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. Basel: MDPI, 2022, roč. 10, č. 10, s. 1-15. ISSN 2227-9059. Dostupné z: https://doi.org/10.3390/biomedicines10102535.

@article{2224424,
   author = {Štork, Martin and Ševčíková, Sabina and Jelinek, Tomas and Minarik, Jiri and Radocha, Jakub and Pika, Tomas and Pospisilova, Lenka and Spicka, Ivan and Straub, Jan and Pavlicek, Petr and Jungova, Alexandra and Knechtová, Zdeňka and Sandecká, Viera and Maisnar, Vladimir and Hajek, Rroman and Pour, Luděk},
   article_location = {Basel},
   article_number = {10},
   doi = {https://doi.org/10.3390/biomedicines10102535},
   keywords = {multiple myeloma; risk factors; survival; plasmacytomas},
   language = {eng},
   issn = {2227-9059},
   journal = {Biomedicines},
   title = {Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas},
   url = {http://mdpi.com/2227-9059/10/10/2535},
   volume = {10},
   year = {2022}
}

TY  - JOUR
ID  - 2224424
AU  - Štork, Martin - Ševčíková, Sabina - Jelinek, Tomas - Minarik, Jiri - Radocha, Jakub - Pika, Tomas - Pospisilova, Lenka - Spicka, Ivan - Straub, Jan - Pavlicek, Petr - Jungova, Alexandra - Knechtová, Zdeňka - Sandecká, Viera - Maisnar, Vladimir - Hajek, Rroman - Pour, Luděk
PY  - 2022
TI  - Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
JF  - Biomedicines
VL  - 10
IS  - 10
SP  - 1-15
EP  - 1-15
PB  - MDPI
SN  - 22279059
KW  - multiple myeloma
KW  - risk factors
KW  - survival
KW  - plasmacytomas
UR  - http://mdpi.com/2227-9059/10/10/2535
N2  - In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients’ data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bone-marrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0–NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and ≥3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4–28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3–67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis.
ER  -

ŠTORK, Martin; Sabina ŠEVČÍKOVÁ; Tomas JELINEK; Jiri MINARIK; Jakub RADOCHA; Tomas PIKA; Lenka POSPISILOVA; Ivan SPICKA; Jan STRAUB; Petr PAVLICEK; Alexandra JUNGOVA; Zdeňka KNECHTOVÁ; Viera SANDECKÁ; Vladimir MAISNAR; Rroman HAJEK a Luděk POUR. Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. \textit{Biomedicines}. Basel: MDPI, 2022, roč.~10, č.~10, s.~1-15. ISSN~2227-9059. Dostupné z: https://doi.org/10.3390/biomedicines10102535.

Přehled o publikaci